COVID-19 Therapeutics Accelerator
The COVID-19 Therapeutics Accelerator (CTA) is an initiative aimed at accelerating the development and deployment of treatment options for the respiratory disease COVID-19 .
It was endowed with $ 125 million seed funding from the Bill & Melinda Gates Foundation , the Wellcome Trust, and the Mastercard Impact Fund and is designed to work with the World Health Organization (WHO), governments and donors, private organizations and corporations, and global institutions.
Initially, drugs that have already been approved are to be tested for their effectiveness against COVID-19. Second, other substances that have already been tested for tolerance are to be identified that may be effective against the virus. Thirdly, new substances and monoclonal antibodies that are suitable for treatment or prophylaxis are being researched.
One goal is to make the products available at affordable prices in poorer countries.
Individual evidence
- ↑ http://www.pmlive.com/pharma_news/gates_foundation,_wellcome_launch_fast-track_covid-19_therapy_fund_1328931
- ↑ https://www.therapeuticsaccelerator.org/frequently-asked-questions/
See also
Access to COVID-19 Tools (ACT) Accelerator